Novyra Pharmachem closes trading window from October 1 for Q2FY27 results
- Trading window closed from October 1, 2026, until 48 hours post-Q2FY27 results declaration
- Restriction applies to Promoters, Directors, KMPs, Insiders, and immediate relatives
- Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015
- Company formerly known as Bansisons Tea Industries Ltd is now Novyra Pharmachem Limited
*this image is generated using AI for illustrative purposes only.
Novyra Pharmachem Limited has closed its trading window for dealing in company securities starting October 1, 2026. The closure remains in effect until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.
This restriction applies to Promoters, members of the Promoter Group, Directors, Key Managerial Personnel (KMPs), Insiders, Designated Persons, Connected Persons, and their immediate relatives. The move is in compliance with SEBI regulations prohibiting insider trading during sensitive periods.
Regulatory Compliance
The trading window closure is implemented pursuant to Clause 4(2) of Schedule B read with Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. It also adheres to SEBI Circulars dated August 5, 2022, and July 19, 2023, alongside the company's internal Code of Internal Procedures and Conduct.
All designated persons are advised against entering into any transactions involving the securities of the company during this period. The date for the Board Meeting to publish the Q2FY27 results will be announced separately.
Corporate Identity Update
The filing was signed by Anilkumar Mohanbhai Amreliya, Director. The document notes that the entity is now operating as Novyra Pharmachem Limited, formerly known as Bansisons Tea Industries Ltd.
Historical Stock Returns for Novyra Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | -44.65% | 0.0% | 0.0% |
How will the strategic pivot from Bansisons Tea Industries to Novyra Pharmachem impact the company's capital allocation and R&D spending in the upcoming fiscal quarters?
What specific revenue growth or margin expansion metrics are analysts anticipating from the Q2FY27 unaudited results to validate the new pharmaceutical identity?
Will the recent corporate rebranding trigger any changes in the company's inclusion in sector-specific indices or institutional investment mandates?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
